TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1,278.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 160,390 shares of the biopharmaceutical company’s stock after buying an additional 148,757 shares during the quarter. Assenagon Asset Management S.A. owned about 0.10% of TG Therapeutics worth $4,781,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TGTX. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at $25,000. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter valued at $25,000. Optiver Holding B.V. boosted its stake in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in TG Therapeutics during the 3rd quarter worth $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. dropped their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Wall Street Zen downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Stock Down 0.7%

Shares of TG Therapeutics stock opened at $31.75 on Friday. TG Therapeutics, Inc. has a one year low of $25.28 and a one year high of $46.48. The company has a market cap of $5.07 billion, a P/E ratio of 11.46 and a beta of 1.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The firm has a fifty day moving average of $29.76 and a two-hundred day moving average of $31.49.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The firm had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company’s revenue was up 78.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.15 earnings per share. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.